Request for Nominations on Device Good Manufacturing Practice Advisory Committee, 31324-31325 [2019-13991]
Download as PDF
khammond on DSKBBV9HB2PROD with NOTICES
31324
Federal Register / Vol. 84, No. 126 / Monday, July 1, 2019 / Notices
Program Name: The National Center
for Benefits Outreach and Enrollment
(NCBOE).
Recipient: National Council on Aging
(NCOA).
Period of Performance: The award
will be issued for the current project
period of September 30, 2017 through
September 29, 2020.
Total Award Amount: $11,390,861 in
FY 2019.
Award Type: Cooperative Agreement
Supplement.
Statutory Authority: The Medicare
Improvements for Patients and
Providers Act of 2008—Section 119,
Public Law (Pub. L.) 110–275 as
amended by the Patient Protection and
Affordable Care Act of 2010 (Affordable
Care Act), reauthorized by the American
Taxpayer Relief Act of 2012 (ATRA) and
reauthorized by section 110 of the
Protecting Access to Medicare Act of
2014.
Basis for Award: The National
Council on Aging (NCOA) is currently
funded to carry out the NCBOE Project
for the period of September 30, 2017
through September 29, 2020. Much
work has already been completed and
further tasks are currently being
accomplished. It would be
unnecessarily time consuming and
disruptive to the NCBOE project and the
beneficiaries being served for the ACL to
establish a new grantee at this time
when critical services are presently
being provided in an efficient manner.
The NCOA is uniquely placed to
complete the work under the NCBOE
grant. Since 2001, the NCOA has been
the national leader in improving
benefits access to vulnerable older
adults. They have an unparalleled
history of working with community
based organizations to develop and
replicate outreach and enrollment
solutions, while maintaining and
enhancing technology to make it easier
and more efficient to find benefits. The
NCOA through NCBOE accomplishes its
mission by developing and sharing
tools, resources, best practices, and
strategies for benefits outreach and
enrollment via its online clearinghouse,
electronic and print publications,
webinars, and training and technical
assistance.
In addition, the NCOA has the
BenefitsCheckUp which is, by far, the
nation’s most comprehensive and
widely-used web-based service that
screens older and disabled adults with
limited incomes and resources and
informs them about public and private
benefits for which they are very likely
to be eligible. Since the
BenefitsCheckUp was launched in 2001,
over 7.6 million individuals have been
VerDate Sep<11>2014
19:58 Jun 28, 2019
Jkt 247001
assisted to identify over $29.6 billion in
potential annual benefits. In addition to
a focus on Low-Income Subsidy and
Medicare Savings Programs, the
BenefitsCheckUp also includes more
than 2,500 benefits programs from all 50
states and DC, including the addition of
Medicaid expansion programs as part of
Affordable Care Act; over 50,000 local
offices for people to apply for benefits;
nearly 2,000 application forms in every
language in which they are available;
and user-friendly mapping tools that
allow streamlined access to program fact
sheets and application forms based
upon a person’s locality.
NCOA is successfully meeting all
programmatic goals under the current
NCBOE grant.
For Further Information Contact: For
further information or comments
regarding this program supplement,
contact Rebecca Kinney, U.S.
Department of Health and Human
Services, Administration for
Community Living, Center for Integrated
Programs, Office of Healthcare
Information and Counseling; telephone
(202) 795–7375; email Rebecca.Kinney@
acl.hhs.gov
Dated: June 24, 2019.
Mary Lazare,
Principal Deputy Administrator.
[FR Doc. 2019–13962 Filed 6–28–19; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2017–N–0809 and FDA–
2018–N–4609]
FOR FURTHER INFORMATION CONTACT:
Althea Cuff, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993–0002,
301–796–4061, Fax: 301–796–9856,
email: althea.cuff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is
announcing the issuance of a priority
review voucher to the sponsor of an
approved rare pediatric disease product
application. Under section 529 of the
FD&C Act (21 U.S.C. 360ff), which was
added by FDASIA, FDA will award
priority review vouchers to sponsors of
approved rare pediatric disease product
applications that meet certain criteria.
FDA has determined that KANUMA
(sebelipase alfa), manufactured by
Alexion Pharmaceuticals Inc., meets the
criteria for a priority review voucher.
KANUMA (sebelipase alfa), is indicated
for the treatment of patients with a
diagnosis of Lysosomal Acid Lipase
deficiency.
For further information about the Rare
Pediatric Disease Priority Review
Voucher Program and for a link to the
full text of section 529 of the FD&C Act,
go to https://www.fda.gov/ForIndustry/
DevelopingProductsforRareDiseases
Conditions/RarePediatricDiseasePriority
VoucherProgram/default.htm. For
further information about KANUMA
(sebelipase alfa), go to the ‘‘Drugs@
FDA’’ website at https://
www.accessdata.fda.gov/scripts/cder/
daf/.
Dated: June 25, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–13944 Filed 6–28–19; 8:45 am]
BILLING CODE 4164–01–P
Issuance of Priority Review Voucher;
Rare Pediatric Disease Product
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Food and Drug Administration
Notice.
The Food and Drug
Administration (FDA) is announcing the
issuance of a priority review voucher to
the sponsor of a rare pediatric disease
product application. The Federal Food,
Drug, and Cosmetic Act (FD&C Act), as
amended by the Food and Drug
Administration Safety and Innovation
Act (FDASIA), authorizes FDA to award
priority review vouchers to sponsors of
approved rare pediatric disease product
applications that meet certain criteria.
FDA is required to publish notice of the
award of the priority review voucher.
FDA has determined that KANUMA
(sebelipase alfa), manufactured by
Alexion Pharmaceuticals Inc., meets the
criteria for a priority review voucher.
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Sfmt 4703
[Docket No. FDA–2019–N–2430]
Request for Nominations on Device
Good Manufacturing Practice Advisory
Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
requesting that any industry
organizations interested in participating
in the selection of a nonvoting industry
representative to serve on the Device
Good Manufacturing Practice Advisory
Committee (DGMPAC) in the Center for
Devices and Radiological Health notify
SUMMARY:
E:\FR\FM\01JYN1.SGM
01JYN1
Federal Register / Vol. 84, No. 126 / Monday, July 1, 2019 / Notices
FDA in writing. FDA is also requesting
nominations for a nonvoting industry
representative to fill an upcoming
vacancy on DGMPAC. A nominee may
either be self-nominated or nominated
by an organization to serve as a
nonvoting industry representative.
Nominations will be accepted for an
upcoming vacancy effective with this
notice.
Any industry organizations
interested in participating in the
selection of an appropriate nonvoting
member to represent industry interests
must send a letter stating that interest to
FDA by July 31, 2019 (see sections I and
III of this document for further details).
Concurrently, nomination materials for
prospective candidates should be sent to
FDA by July 31, 2019.
DATES:
All statements of interest
from industry organizations interested
in participating in the selection process
of nonvoting industry representative
nominations should be sent to Margaret
Ames (see FOR FURTHER INFORMATION
CONTACT). All nominations for
nonvoting industry representatives
should be submitted electronically by
accessing FDA’s Advisory Committee
Membership Nomination Portal at
https://www.accessdata.fda.gov/scripts/
FACTRSPortal/FACTRS/index.cfm or by
mail to Advisory Committee Oversight
and Management Staff, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5103, Silver Spring,
MD 20993–0002. Information about
becoming a member of an FDA advisory
committee can also be obtained by
visiting FDA’s website at https://
www.fda.gov/AdvisoryCommittees/
default.htm.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Margaret Ames, Office of Management,
Center for Devices and Radiological
Health, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 66,
Rm. 5264, Silver Spring, MD 20993–
0002, 301–796–5960, Fax: 301–847–
8505, email: Margaret.Ames@
fda.hhs.gov.
Section
520 of the Federal Food, Drug and
Cosmetic Act (21 U.S.C. 360j), as
amended, provides that DGMPAC shall
be composed of two representatives of
interests of the device manufacturing
industry. The Agency is requesting
nominations for a nonvoting industry
representative to fill an upcoming
vacancy on DGMPAC. FDA is
publishing a separate document
announcing the request for notification
for voting members on DGMPAC.
khammond on DSKBBV9HB2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
19:58 Jun 28, 2019
Jkt 247001
I. Function of DGMPAC
DGMPAC reviews proposed
regulations regarding good
manufacturing practices governing the
methods used in, and the facilities and
controls used for, the manufacture,
packaging, storage, installation, and
servicing of devices, and makes
recommendations regarding the
feasibility and reasonableness of those
proposed regulations. The committee
also reviews and makes
recommendations on proposed guidance
developed to assist the medical device
industry in meeting the good
manufacturing practice requirements
and provides advice with regard to any
petition submitted by a manufacturer for
an exemption or variance from good
manufacturing practice regulations.
II. Qualifications
Persons nominated for DGMPAC
should possess appropriate
qualifications to understand and
contribute to the committee’s work as
described in the committee’s function.
III. Selection Procedure
Any industry organization interested
in participating in the selection of an
appropriate nonvoting member to
represent industry interests should send
a letter stating that interest to the FDA
contact (see FOR FURTHER INFORMATION
CONTACT) within 30 days of publication
of this document (see DATES). Within the
subsequent 30 days, FDA will send a
letter to each organization that has
expressed an interest, attaching a
complete list of all such organizations,
and a list of all nominees along with
their current re´sume´. The letter will also
state that it is the responsibility of the
interested organizations to confer with
one another and to select a candidate,
within 60 days after the receipt of the
FDA letter, to serve as the nonvoting
member to represent industry interests
for the committee. The interested
organizations are not bound by the list
of nominees in selecting a candidate.
However, if no individual is selected
within 60 days, the Commissioner will
select the nonvoting member to
represent industry interests.
IV. Application Procedure
Individuals may self-nominate and/or
an organization may nominate one or
more individuals to serve as a nonvoting
industry representative. Nominations
must include a current, complete
re´sume´ or curriculum vitae for each
nominee, including current business
address, telephone number, email
address if available, and a signed copy
of the Acknowledgement and Consent
form available at the FDA Advisory
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
31325
Committee Membership Nomination
Portal (see ADDRESSES) within 30 days of
publication of this document (see
DATES). Nominations must also specify
the advisory committee for which the
nominee is recommended. Nominations
must also acknowledge that the
nominee is aware of the nomination
unless self-nominated. FDA will
forward all nominations to the
organizations expressing interest in
participating in the selection process for
the committee. (Persons who nominate
themselves as nonvoting industry
representatives will not participate in
the selection process.)
FDA seeks to include the views of
women and men, members of all racial
and ethnic groups, and individuals with
and without disabilities on its advisory
committees and, therefore, encourages
nominations of appropriately qualified
candidates from these groups.
Specifically, in this document,
nominations for nonvoting
representatives of industry interests are
encouraged from the device
manufacturing industry.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: June 26, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–13991 Filed 6–28–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–D–2016]
Epidermolysis Bullosa: Developing
Drugs for Treatment of Cutaneous
Manifestations; Guidance for Industry;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a final
guidance for industry entitled
‘‘Epidermolysis Bullosa: Developing
Drugs for Treatment of Cutaneous
Manifestations.’’ The purpose of this
guidance is to assist sponsors with the
development of drugs for treatment or
prevention of the serious cutaneous
manifestations of the heterogeneous
group of disorders collectively known as
epidermolysis bullosa (EB). This
guidance focuses on drug development
SUMMARY:
E:\FR\FM\01JYN1.SGM
01JYN1
Agencies
[Federal Register Volume 84, Number 126 (Monday, July 1, 2019)]
[Notices]
[Pages 31324-31325]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-13991]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2019-N-2430]
Request for Nominations on Device Good Manufacturing Practice
Advisory Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is requesting
that any industry organizations interested in participating in the
selection of a nonvoting industry representative to serve on the Device
Good Manufacturing Practice Advisory Committee (DGMPAC) in the Center
for Devices and Radiological Health notify
[[Page 31325]]
FDA in writing. FDA is also requesting nominations for a nonvoting
industry representative to fill an upcoming vacancy on DGMPAC. A
nominee may either be self-nominated or nominated by an organization to
serve as a nonvoting industry representative. Nominations will be
accepted for an upcoming vacancy effective with this notice.
DATES: Any industry organizations interested in participating in the
selection of an appropriate nonvoting member to represent industry
interests must send a letter stating that interest to FDA by July 31,
2019 (see sections I and III of this document for further details).
Concurrently, nomination materials for prospective candidates should be
sent to FDA by July 31, 2019.
ADDRESSES: All statements of interest from industry organizations
interested in participating in the selection process of nonvoting
industry representative nominations should be sent to Margaret Ames
(see FOR FURTHER INFORMATION CONTACT). All nominations for nonvoting
industry representatives should be submitted electronically by
accessing FDA's Advisory Committee Membership Nomination Portal at
https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm or
by mail to Advisory Committee Oversight and Management Staff, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103,
Silver Spring, MD 20993-0002. Information about becoming a member of an
FDA advisory committee can also be obtained by visiting FDA's website
at https://www.fda.gov/AdvisoryCommittees/default.htm.
FOR FURTHER INFORMATION CONTACT: Margaret Ames, Office of Management,
Center for Devices and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5264, Silver
Spring, MD 20993-0002, 301-796-5960, Fax: 301-847-8505, email:
[email protected].
SUPPLEMENTARY INFORMATION: Section 520 of the Federal Food, Drug and
Cosmetic Act (21 U.S.C. 360j), as amended, provides that DGMPAC shall
be composed of two representatives of interests of the device
manufacturing industry. The Agency is requesting nominations for a
nonvoting industry representative to fill an upcoming vacancy on
DGMPAC. FDA is publishing a separate document announcing the request
for notification for voting members on DGMPAC.
I. Function of DGMPAC
DGMPAC reviews proposed regulations regarding good manufacturing
practices governing the methods used in, and the facilities and
controls used for, the manufacture, packaging, storage, installation,
and servicing of devices, and makes recommendations regarding the
feasibility and reasonableness of those proposed regulations. The
committee also reviews and makes recommendations on proposed guidance
developed to assist the medical device industry in meeting the good
manufacturing practice requirements and provides advice with regard to
any petition submitted by a manufacturer for an exemption or variance
from good manufacturing practice regulations.
II. Qualifications
Persons nominated for DGMPAC should possess appropriate
qualifications to understand and contribute to the committee's work as
described in the committee's function.
III. Selection Procedure
Any industry organization interested in participating in the
selection of an appropriate nonvoting member to represent industry
interests should send a letter stating that interest to the FDA contact
(see FOR FURTHER INFORMATION CONTACT) within 30 days of publication of
this document (see DATES). Within the subsequent 30 days, FDA will send
a letter to each organization that has expressed an interest, attaching
a complete list of all such organizations, and a list of all nominees
along with their current r[eacute]sum[eacute]. The letter will also
state that it is the responsibility of the interested organizations to
confer with one another and to select a candidate, within 60 days after
the receipt of the FDA letter, to serve as the nonvoting member to
represent industry interests for the committee. The interested
organizations are not bound by the list of nominees in selecting a
candidate. However, if no individual is selected within 60 days, the
Commissioner will select the nonvoting member to represent industry
interests.
IV. Application Procedure
Individuals may self-nominate and/or an organization may nominate
one or more individuals to serve as a nonvoting industry
representative. Nominations must include a current, complete
r[eacute]sum[eacute] or curriculum vitae for each nominee, including
current business address, telephone number, email address if available,
and a signed copy of the Acknowledgement and Consent form available at
the FDA Advisory Committee Membership Nomination Portal (see ADDRESSES)
within 30 days of publication of this document (see DATES). Nominations
must also specify the advisory committee for which the nominee is
recommended. Nominations must also acknowledge that the nominee is
aware of the nomination unless self-nominated. FDA will forward all
nominations to the organizations expressing interest in participating
in the selection process for the committee. (Persons who nominate
themselves as nonvoting industry representatives will not participate
in the selection process.)
FDA seeks to include the views of women and men, members of all
racial and ethnic groups, and individuals with and without disabilities
on its advisory committees and, therefore, encourages nominations of
appropriately qualified candidates from these groups. Specifically, in
this document, nominations for nonvoting representatives of industry
interests are encouraged from the device manufacturing industry.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: June 26, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-13991 Filed 6-28-19; 8:45 am]
BILLING CODE 4164-01-P